Business Description
Candel Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1374041093
Description
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.03 | |||||
| Equity-to-Asset | -0.71 | |||||
| Debt-to-Equity | -1.05 | |||||
| Debt-to-EBITDA | -0.33 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -19.3 | |||||
| 3-Year EPS without NRI Growth Rate | -24.3 | |||||
| 3-Year FCF Growth Rate | -28.6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.81 | |||||
| 9-Day RSI | 50.45 | |||||
| 14-Day RSI | 46.56 | |||||
| 6-1 Month Momentum % | -37.94 | |||||
| 12-1 Month Momentum % | 534.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.18 | |||||
| Quick Ratio | 1.18 | |||||
| Cash Ratio | 1.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.8 | |||||
| Shareholder Yield % | -2.97 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -1580.16 | |||||
| ROA % | -153.09 | |||||
| ROIC % | -262.71 | |||||
| ROC (Joel Greenblatt) % | -1326.29 | |||||
| ROCE % | -241.48 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -3.06 | |||||
| EV-to-Forward-EBIT | -4.1 | |||||
| EV-to-EBITDA | -3.12 | |||||
| EV-to-Forward-EBITDA | -4.12 | |||||
| EV-to-Forward-Revenue | 2.03 | |||||
| EV-to-FCF | -5.31 | |||||
| Earnings Yield (Greenblatt) % | -32.68 | |||||
| FCF Yield % | -18.78 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CADL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Candel Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.73 | ||
| Beta | -0.81 | ||
| Volatility % | 354.68 | ||
| 14-Day RSI | 46.56 | ||
| 14-Day ATR ($) | 0.452217 | ||
| 20-Day SMA ($) | 4.63225 | ||
| 12-1 Month Momentum % | 534.3 | ||
| 52-Week Range ($) | 0.77 - 14.3 | ||
| Shares Outstanding (Mil) | 32.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Candel Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Candel Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Candel Therapeutics Inc Frequently Asked Questions
What is Candel Therapeutics Inc(CADL)'s stock price today?
The current price of CADL is $4.71. The 52 week high of CADL is $14.30 and 52 week low is $0.77.
When is next earnings date of Candel Therapeutics Inc(CADL)?
The next earnings date of Candel Therapeutics Inc(CADL) is 2025-03-28 Est..
Does Candel Therapeutics Inc(CADL) pay dividends? If so, how much?
Candel Therapeutics Inc(CADL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers